News

12.09.24

Press Release

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

SEATTLE and VANCOUVER, British Columbia, December 9, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr….

/Read More

12.03.24

Press Release

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation SEATTLE and VANCOUVER, British Columbia – December 3, 2024 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today the successful outcome of its End-of-Phase 2 meeting with…

/Read More

11.14.24

Press Release

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, November 14, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Rick Stewart, CEO of Achieve Life Sciences, and management will be participating at two upcoming investor…

/Read More

11.07.24

Press Release

Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Company to host conference call at 4:30 PM EST today, Thursday, November 7, 2024 SEATTLE and VANCOUVER, British Columbia, November 7, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced its financial results…

/Read More

10.24.24

Press Release

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024

SEATTLE and VANCOUVER, British Columbia, October 24, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline…

/Read More